Literature DB >> 23273594

A possible role for systemic hypoxia in the reactive component of pulmonary hypertension in heart failure.

Bryan J Taylor1, Cesar R Mojica, Thomas P Olson, Paul R Woods, Robert P Frantz, Bruce D Johnson.   

Abstract

BACKGROUND: The mechanisms underlying the reactive component of pulmonary hypertension (PH) in heart failure (HF) are unclear. We examined whether resting systemic oxygen levels are related to pulmonary hemodynamics in HF. METHODS AND
RESULTS: Thirty-nine HF patients underwent right heart catheterization. Subsequently, patients were classified as having: 1) no PH (n = 12); 2) passive PH (n = 10); or 3) reactive PH (n = 17). Blood was drawn from the radial and pulmonary arteries for the determination of PaO(2), SaO(2), PvO(2), SvO(2), and vasoactive neurohormones. PaO(2) and PvO(2) were lower in reactive PH versus no PH and passive PH patients (65.3 ± 8.6 vs 78.3 ± 11.4 mm Hg and 74.5 ± 14.0 mm Hg; 29.2 ± 4.1 vs 36.2 ± 2.8 mm Hg and 33.4 ± 2.3 mm Hg; P < .05). SaO(2) and SvO(2) were lower in reactive PH versus no PH patients (93 ± 3% vs 96 ± 3%; 51 ± 11% vs 68 ± 4%; P < .05), but not different versus passive PH patients. The transpulmonary pressure gradient (TPG) was inversely related to PaO(2), PvO(2), SaO(2), and SvO(2) in the reactive PH patients only (r ≤ -0.557; P < .05). Similarly, plasma endothelin-1 correlated with PaO(2), PvO(2), SvO(2) (r ≤ -0.495), and TPG (r = 0.662; P < .05) in reactive PH patients only.
CONCLUSIONS: Systemic hypoxia may play a role in the reactive component of PH in HF, potentially via a hypoxia-induced increase in endothelial release of the vasoconstrictor endothelin-1.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23273594      PMCID: PMC3541409          DOI: 10.1016/j.cardfail.2012.11.005

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  46 in total

1.  A continuous spectrophotometric assay for angiotensin converting enzyme.

Authors:  B Holmquist; P Bünning; J F Riordan
Journal:  Anal Biochem       Date:  1979-06       Impact factor: 3.365

2.  Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction.

Authors:  J M Post; J R Hume; S L Archer; E K Weir
Journal:  Am J Physiol       Date:  1992-04

3.  Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy.

Authors:  S V Abramson; J F Burke; J J Kelly; J G Kitchen; M J Dougherty; D F Yih; F C McGeehin; J W Shuck; T P Phiambolis
Journal:  Ann Intern Med       Date:  1992-06-01       Impact factor: 25.391

4.  Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities.

Authors:  M J Sullivan; M B Higginbotham; F R Cobb
Journal:  Circulation       Date:  1988-03       Impact factor: 29.690

5.  Hypoxic constriction of porcine distal pulmonary arteries: endothelium and endothelin dependence.

Authors:  Q Liu; J S Sham; L A Shimoda; J T Sylvester
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-05       Impact factor: 5.464

6.  Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study.

Authors:  Pietro Amedeo Modesti; Simone Vanni; Marco Morabito; Alessandra Modesti; Matilde Marchetta; Tania Gamberi; Francesco Sofi; Giulio Savia; Giuseppe Mancia; Gian Franco Gensini; Gianfranco Parati
Journal:  Circulation       Date:  2006-09-18       Impact factor: 29.690

7.  Arterial oxygenation and arterial oxygen transport in chronic myocardial failure at rest, during exercise and after hydralazine treatment.

Authors:  S A Rubin; H V Brown; H J Swan
Journal:  Circulation       Date:  1982-07       Impact factor: 29.690

8.  Increased arterial oxygen content--an important compensatory mechanism in chronic moderate heart failure.

Authors:  B Herrlin; C Sylvén
Journal:  Cardiovasc Res       Date:  1991-05       Impact factor: 10.787

9.  Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure.

Authors:  D P Moore; A R Weston; J M Hughes; C M Oakley; J G Cleland
Journal:  Lancet       Date:  1992-04-04       Impact factor: 79.321

10.  Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure.

Authors:  R J Cody; G J Haas; P F Binkley; Q Capers; R Kelley
Journal:  Circulation       Date:  1992-02       Impact factor: 29.690

View more
  4 in total

1.  Submaximal Exercise Pulmonary Gas Exchange in Left Heart Disease Patients With Different Forms of Pulmonary Hypertension.

Authors:  Bryan J Taylor; Michael R Smetana; Robert P Frantz; Bruce D Johnson
Journal:  J Card Fail       Date:  2015-04-14       Impact factor: 5.712

2.  Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars.

Authors:  Mingzhou Li; Shilin Tian; Long Jin; Guangyu Zhou; Ying Li; Yuan Zhang; Tao Wang; Carol K L Yeung; Lei Chen; Jideng Ma; Jinbo Zhang; Anan Jiang; Ji Li; Chaowei Zhou; Jie Zhang; Yingkai Liu; Xiaoqing Sun; Hongwei Zhao; Zexiong Niu; Pinger Lou; Lingjin Xian; Xiaoyong Shen; Shaoqing Liu; Shunhua Zhang; Mingwang Zhang; Li Zhu; Surong Shuai; Lin Bai; Guoqing Tang; Haifeng Liu; Yanzhi Jiang; Miaomiao Mai; Jian Xiao; Xun Wang; Qi Zhou; Zhiquan Wang; Paul Stothard; Ming Xue; Xiaolian Gao; Zonggang Luo; Yiren Gu; Hongmei Zhu; Xiaoxiang Hu; Yaofeng Zhao; Graham S Plastow; Jinyong Wang; Zhi Jiang; Kui Li; Ning Li; Xuewei Li; Ruiqiang Li
Journal:  Nat Genet       Date:  2013-10-27       Impact factor: 38.330

Review 3.  Exercise Intolerance in Heart Failure: Central Role for the Pulmonary System.

Authors:  Sophie Lalande; Troy J Cross; Manda L Keller-Ross; Norman R Morris; Bruce D Johnson; Bryan J Taylor
Journal:  Exerc Sport Sci Rev       Date:  2020-01       Impact factor: 6.642

Review 4.  Pulmonary Hypertension and Cardiopulmonary Exercise in Heart Failure.

Authors:  Chul-Ho Kim; Sae Young Jae; Bruce D Johnson
Journal:  Pulse (Basel)       Date:  2014-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.